These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26762168)

  • 1. Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
    Penttinen AM; Suleymanova I; Albert K; Anttila J; Voutilainen MH; Airavaara M
    J Neurosci Res; 2016 Apr; 94(4):318-28. PubMed ID: 26762168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical changes of nigrostriatal tyrosine hydroxylase and dopamine transporter in the golden hamster after a single intrastriatal injection of 6-hydroxydopamine.
    Rodríguez S; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 May; 65(4):463-8. PubMed ID: 22357095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study.
    Healy-Stoffel M; Ahmad SO; Stanford JA; Levant B
    J Neurosci Methods; 2012 Sep; 210(2):187-94. PubMed ID: 22850559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.
    Oiwa Y; Sanchez-Pernaute R; Harvey-White J; Bankiewicz KS
    J Neurosurg; 2003 Jan; 98(1):136-44. PubMed ID: 12546362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
    Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
    Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of electrolytic and 6-hydroxydopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase.
    Gomes MZ; Del Bel EA
    Brain Res Bull; 2003 Dec; 62(2):107-15. PubMed ID: 14638384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal TH-immunopositive fibers recover after an intrastriatal injection of 6-hydroxydopamine in golden hamsters treated with prednisolone: roles of tumor necrosis factor-α and inducible nitric oxide synthase in neurodegeneration.
    Rodríguez S; Uchida K; Nakayama H
    Neurosci Res; 2013; 76(1-2):83-92. PubMed ID: 23471013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Han B; Jin HJ; Song MY; Wang T; Zhao H
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: implications for abnormal motor behavior.
    Anaya-Martinez V; Martinez-Marcos A; Martinez-Fong D; Aceves J; Erlij D
    Neuroscience; 2006 Dec; 143(2):477-86. PubMed ID: 17008017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
    Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
    eNeuro; 2017; 4(1):. PubMed ID: 28303260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.
    Boix J; Padel T; Paul G
    Behav Brain Res; 2015 May; 284():196-206. PubMed ID: 25698603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus.
    Debeir T; Ginestet L; François C; Laurens S; Martel JC; Chopin P; Marien M; Colpaert F; Raisman-Vozari R
    Exp Neurol; 2005 Jun; 193(2):444-54. PubMed ID: 15869947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.
    Kondoh T; Bannai M; Nishino H; Torii K
    Exp Neurol; 2005 Mar; 192(1):194-202. PubMed ID: 15698634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.